Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis

J.S. Smolen, M. Boers, E.C. Abadie, F.C. Breedveld, P Emery, T Bardin, N. Goel, D.J. Ethgen, B.P. Avouac, P. Durez, B. Flamion, A. Laslop, P. Miossec, S. Reiter, J.Y. Reginster

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1732-1736
JournalRheumatology
Volume50
Issue number10
DOIs
Publication statusPublished - 2011

Cite this

Smolen, J.S. ; Boers, M. ; Abadie, E.C. ; Breedveld, F.C. ; Emery, P ; Bardin, T ; Goel, N. ; Ethgen, D.J. ; Avouac, B.P. ; Durez, P. ; Flamion, B. ; Laslop, A. ; Miossec, P. ; Reiter, S. ; Reginster, J.Y. / Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. In: Rheumatology. 2011 ; Vol. 50, No. 10. pp. 1732-1736.
@article{6ffe46ef15b74422ad2ae4cc8ffcb8bd,
title = "Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis",
author = "J.S. Smolen and M. Boers and E.C. Abadie and F.C. Breedveld and P Emery and T Bardin and N. Goel and D.J. Ethgen and B.P. Avouac and P. Durez and B. Flamion and A. Laslop and P. Miossec and S. Reiter and J.Y. Reginster",
year = "2011",
doi = "10.1093/rheumatology/keq413",
language = "Undefined/Unknown",
volume = "50",
pages = "1732--1736",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "10",

}

Smolen, JS, Boers, M, Abadie, EC, Breedveld, FC, Emery, P, Bardin, T, Goel, N, Ethgen, DJ, Avouac, BP, Durez, P, Flamion, B, Laslop, A, Miossec, P, Reiter, S & Reginster, JY 2011, 'Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis' Rheumatology, vol. 50, no. 10, pp. 1732-1736. https://doi.org/10.1093/rheumatology/keq413

Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. / Smolen, J.S.; Boers, M.; Abadie, E.C.; Breedveld, F.C.; Emery, P; Bardin, T; Goel, N.; Ethgen, D.J.; Avouac, B.P.; Durez, P.; Flamion, B.; Laslop, A.; Miossec, P.; Reiter, S.; Reginster, J.Y.

In: Rheumatology, Vol. 50, No. 10, 2011, p. 1732-1736.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis

AU - Smolen, J.S.

AU - Boers, M.

AU - Abadie, E.C.

AU - Breedveld, F.C.

AU - Emery, P

AU - Bardin, T

AU - Goel, N.

AU - Ethgen, D.J.

AU - Avouac, B.P.

AU - Durez, P.

AU - Flamion, B.

AU - Laslop, A.

AU - Miossec, P.

AU - Reiter, S.

AU - Reginster, J.Y.

PY - 2011

Y1 - 2011

U2 - 10.1093/rheumatology/keq413

DO - 10.1093/rheumatology/keq413

M3 - Article

VL - 50

SP - 1732

EP - 1736

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 10

ER -